NCT06962891View on ClinicalTrials.gov

Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease

Active, not recruitingOBSERVATIONAL
Enrollment

213

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

May 1, 2026

Conditions
Chronic Kidney Disease(CKD)Progression, Disease
Interventions
DIAGNOSTIC_TEST

CKD progression biomarker

We will evaluate the CKD progression biomarker at baseline and evaluate 1-year CKD progression afterwards.

Trial Locations (3)

6020

Medizinische Universität Innsbruck, Innsbruck

34200

Néphrologie Dialyse St Guilhem, Sète

95445

Klinikum Bayreuth GmbH, Bayreuth

Sponsors

Lead Sponsor

Angel Argiles
All Listed Sponsors
collaborator

Medical University Innsbruck

OTHER

collaborator

Klinikum Bayreuth GmbH

INDUSTRY

collaborator

University of Skövde

OTHER

collaborator

RWTH Aachen University

OTHER

collaborator

RD Néphrologie SAS

INDUSTRY

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

University Paul Sabatier of Toulouse

OTHER

lead

Angel Argiles

INDUSTRY

NCT06962891 - Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease | Biotech Hunter | Biotech Hunter